Purpose Opioids are recommended for moderate to severe cancer pain; however, in patients with cancer, impaired renal function can affect opioid metabolism. The aim of this systematic review was to evaluate the current evidence for the use of opioids in cancer patients with renal impairment. Methods A systematic review was conducted and the following databases were searched: MEDLINE (1966MEDLINE ( to 2015, EMBASE (1980EMBASE ( 2015 and Cochrane Central Register of Controlled Trials (up to 2015). Eligible studies met the following criteria: patients with cancer pain taking an opioid (defined as per the WHO ladder); >18 years; renal impairment (serum creatinine > normal range (study dependent), creatinine clearance (CrCl) or glomerular filtration rate (GFR) measurements <90 ml/min, or as per the study definition); clinical outcome related to renal impairment. All eligible studies were appraised using the Grading of Recommendation Assessment, Development and Evaluations (GRADE) system. Results Eighteen studies (n = 2422) were eligible but heterogeneity meant meta-analysis was not possible. Morphine was examined in eight studies (n = 1418), oxycodone in two studies (n = 325), and fentanyl, alfentanil or sufentanil were discussed in six studies in total (n = 442). No recommendations could be formulated on the preferred opioid in patients with renal impairment. Conclusion There is lack of consensus within the existing literature on the relationship between morphine, creatinine levels and morphine-related side effects. Based on the current evidence, morphine should be used with caution; however, more evidence is needed. Fentanyl, alfentanil and sufentanil are recommended in patients with renal impairment based on pharmacokinetics and clinical experience. However, the present systematic review found very little clinical evidence for this. Overall, the quality of the existing evidence on opioid treatment in cancer patients with renal impairment is low. There remains a need for high-quality clinical studies examining opioids in patients with renal impairment.
Background
Patients with cancer may have renal impairment due to cancer treatment and/or the disease itself. To illustrate, approximately 60 % of patients with cancer have been found to have a creatinine clearance <90 ml/min, and 20 % have a creatinine clearance <60 ml/min [1] .
This can present some challenges, as opioids are the mainstay of treatment for moderate to severe cancer pain [2] . Impaired renal function changes opioid metabolism, particularly the half-life, due to several factors. Reduced excretion results in the accumulation of opioid metabolites. This is compounded by changes in hepatic metabolism such as changes in hepatic blood flow, induction of hepatic enzymes, altered protein binding and altered bioavailability [3] . These alterations in the normal physiological processes mean that using opioids in patients with renal impairment is not Electronic supplementary material The online version of this article (doi:10.1007/s00520-016-3447-0) contains supplementary material, which is available to authorized users.
straightforward. However, it is important that an understanding of opioid metabolism in this setting is appreciated to balance the analgesic effects of opioids with any side effects.
To date, there has been limited research examining the use of opioids in cancer patients with renal impairment. Although guidelines have been developed, these have been based on known opioid pharmacokinetics and expert opinions, rather than a strong evidence base [4] . Subsequently, there has been a variation in physicians' practise in assessment of renal function and the choice of opioids in accordance to the effect on the renal function [5] . An understanding of the evidence examining opioids in patients with renal impairment is needed. Therefore, the aim of this systematic review was to assess the current evidence for the use of opioids in cancer patients with renal impairment.
Methods
Ethical approval was not required for this systematic review. The electronic bibliographic databases MEDLINE (1966 to September week 3 2015), EMBASE (1980 to September week 3 2015) and Cochrane Central Register of Controlled Trials (setup to 24th of September 2015) were searched.
Search strategy
An extensive literature search was done, using free text and MeSH/EMTREE search terms. Searches were limited to studies published in the English language. The search strategy is shown in Appendix 1. Hand searching of reference lists of included studies and review articles was also undertaken.
Eligible studies met the following criteria:
& Patients with cancer-related pain, taking an opioid (as defined by the WHO analgesic ladder for cancer pain relief) & >18 years of age & Patients with renal impairment, defined as serum creatinine above the normal range (study dependent), creatinine clearance (CrCl) or glomerular filtration rate (GFR) measurements <90 ml/min, or as per the study definition & Clinical outcome related to renal impairment & Primary studies
Excluded studies assessed the longer-term efficacy of opioids during dialysis, case reports on one single patient (n = 1) and studies not reported in the English language.
Appraisal
Following the literature search, the titles of all studies were reviewed and studies deemed not relevant were excluded. Then, the abstracts of all remaining studies were reviewed, and again, non-relevant studies were excluded. Subsequently, full-text studies were retrieved and evaluated.
Due to variations in study populations, outcome measures and opioid, meta-analysis was not possible. Instead studies were grouped as per primary opioid and discussed thus. Where possible, all studies had their degree of renal impairment classified according to the Kidney Disease Improving Global Outcomes (KDIGO) guidelines [6] .
The content and quality of the included studies were assessed by two authors independently (TS and BL), using the Grading of Recommendations Assessment Development and Evaluations (GRADE) criteria [7] . Factors evaluated when applying these criteria included study design, possible study limitations (allocation concealment, large losses to follow-up, no ITT analysis carried out, early stopping for benefit and failure to report outcomes), participants, setting and results [7] .
Results
The literature search and appraisal process are shown in Fig. 1 . The database searches retrieved a total of 640 studies. Removal of 54 duplicates left 586 studies for further evaluation. Hand search of reference lists of included studies, relevant chapters and review articles revealed another 16 studies, making 602 studies in total. Eighteen studies (n = 2422) remained after applying the inclusion and exclusion criteria
Papers for assessment n=602
Papers included n=18
Exclusion based on abstract n=584
Removal of duplicates n=54
Hand-search from reference lists n=16 Fig. 1 Selection of relevant papers [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . The included studies are shown in Table 1 . The most common causes for exclusion were that opioid treatment was not given for cancer-related pain, studies on opioid treatment during dialysis and publications that were case reports.
Morphine
Eight studies assessed aspects of morphine and/or its metabolites [8, 11, 12, [17] [18] [19] [20] 23] . Morphine is metabolised in the liver to two major metabolites, morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G), both of which are excreted in the urine. M3G is an inactive metabolite, while M6G is active and more potent than morphine itself [26] .
One of the first studies to examine the relationship between morphine plasma concentrations and side effects in patients with cancer, was published by Somogyi et al. [19] . In this small study (n = 11), they observed that the average steadystate plasma concentrations of morphine, M3G and M6G were related to the morphine dose per kilogramme of bodyweight (p < 0.01). They also found that the renal clearance of M3G and M6G were closely related (r 2 = 0.80; p < 0.0005). No relationship was found between renal clearance of morphine, M3G and M6G, and that of creatinine. No relationship was found between plasma morphine and M6G concentrations and pain relief (only evaluated with visual inspection). On the same theme, Tiseo et al. published a non-randomised cohort study (n = 109) in patients with cancer [20] . The relationship between M6G and opioid-related side effects was assessed, and a moderate but significant correlation was demonstrated between M6G/morphine ratio and blood urea nitrogen (BUN) (r = 0.4, p < 0.001) and creatinine (r = 0.45; p < 0.001). These findings were echoed by another study that demonstrated significantly higher concentrations of plasma M3G, M6G and dose-corrected plasma M3G and M6G in patients with serum creatinine levels above normal range (p < 0.001) [8] .
Taking this further by assessing how morphine metabolites were related to opioid side effects, Tiseo et al. observed that a higher creatinine level did not relate to the likelihood of side effects: i.e. patients with a high creatinine did not have any more side effects than those with a low creatinine [20] . This finding was supported by another study which showed no relationship between serum concentrations of morphine, M3G, M6G and pain intensity or opioid-induced side effects (nausea, constipation, sedation and cognitive failure evaluated) [11] . However, other work has demonstrated significant correlations between cognitive function and plasma morphine concentrations (p < 0.05) and between higher mean serum creatinine and worse cognitive function in patients with nausea and vomiting adverse effects (p < 0.05) [23] .
Another important clinical aspect is identifying predictors of morphine intolerance. In 2004, a non-randomised retrospective study compared patients who were morphinetolerant with those who were morphine-intolerant. Age over 78 years (p < 0.03), high white cell count (p < 0.002), high platelet count (p < 0.003) and poor liver or renal function were all identified as predictors for higher risk of morphine intolerance. A follow-up study compared patients treated with morphine for at least 4 weeks with good response (termed Bresponders^) to patients with poor pain control and/or intolerable side effects on morphine treatment (termed Bswitchers^) [18] . Combining all these aspects, the most recent study in this area was published in 2015. The relationship between symptoms and/or adverse effects (fatigue, nausea/vomiting, pain, appetite, constipation and cognitive dysfunction, assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ-C30], scores transformed into 0-100 scales) and renal function was assessed in 1147 cancer patients on opioid treatment [12] . In this study, morphine, oxycodone and fentanyl were all evaluated, and the patients included were exclusively taking one of these three opioids. For morphine, patients with higher serum concentrations were more likely to have severe constipation (OR 1.73; 95 % CI 1.13-2.65; p < 0.001) and severe cognitive dysfunction (OR 1.77; 95 % CI 1.13-2.78; p < 0.01) than patients with lower morphine serum concentrations. Patients with higher M3G serum concentration were more likely to have severe cognitive dysfunction (OR 1.63; 95 % CI 1.03-2.56; p = 0.04) than patients with lower M3G serum concentrations. M6G was not associated with any of the side effects evaluated. Patients with moderate/severe and mild renal impairment (<90 ml/min/1.73 m 2 ) and being treated with morphine had significantly higher odds of having severe constipation (OR 1.91; 95 % CI 1.08-3.37 and OR 1.80; 95 % CI 1.18-2.75, respectively) compared with patients with normal renal function (≥90 ml/min/1.73 m 2 ).
Oxycodone
Only two eligible studies examined oxycodone [15] . This was an uncontrolled prospective study published by Narabayashi et al. in 2008 , assessing the effect on pain control when rotating from oral morphine to oxycodone in 27 patients with 14 Medical institutions in Japan, cancer inpatients, ≥20 years.
Pts. with no renal impairment (n = 18), s-creatinine ≤1.5
times the upper limit of normal. Pts. with renal impairment (n = 9), estimated creatinine clearance <60 ml/min intolerable side effects on morphine. Overall, 21/25 (84 %) of the patients achieved adequate pain control on the oxycodone treatment. Acceptability (rated by the patient on a categorical scale 1-5) was significantly improved from study entry when the patients were treated with morphine to the end of the study when the patients were treated with oxycodone (p < 0.0004). No significant correlation was found between creatinine clearance and oxycodone or its metabolites (no p value reported). In addition to this study, the retrospective cohort study by Kurita et al. discussed above also evaluated whether symptoms and adverse effects are associated with renal function in patients treated with oxycodone [12] . The authors found that patients with higher serum concentrations of oxycodone were more likely to report severe fatigue (OR 1.70; 95 % CI 1.04-2.78; p = 0.03) than were patients with lower oxycodone serum concentrations. The metabolite noroxycodone was not associated with any of the side effects evaluated.
Fentanyl
One study exclusively assessed aspects of fentanyl [25] . Mazzocato et al. retrospectively reviewed the records of 53 patients (33 of them were patients with cancer) followed by a palliative care consultant team in a tertiary hospital in Switzerland. The patients had renal impairment (calculated GFR <60 ml/min) and were treated with subcutaneous fentanyl. Pain control was complete in 31/53 (59 %) of patients and partial in 14/53 (26 %) of patients. In patients that had experienced neurotoxic symptoms thought to be opioid-related, the symptoms resolved completely in 8/26 (31 %) and partly in 6/ 26 (26 %) of patients.
In addition to this study, the retrospective cohort study by Kurita et al. discussed above also reported on fentanyl [12] . Neither fentanyl nor its metabolite norfentanyl were associated with any of the side effects evaluated.
Alfentanil
Two studies examined aspects of alfentanil [10, 21] . Urch et al. reviewed the records of 48 patients treated with alfentanil [21] . The authors investigated the interaction between alfentanil and commonly prescribed inducers and inhibitors of the cytochrome P450 system, which alfentanil is metabolised by. Concomitant prescription of at least one drug that interferes with cytochrome P450 occurred in 75 % of cases. No significant correlation was found between dose escalation and concomitant drugs that interfere with the P450 system.
The study by Kirkham et al. from 1995 reported on four patients with renal impairment, who were intolerant to subcutaneous diamorphine [10] . The authors reported that the patients' agitation settled after they were switched to subcutaneous alfentanil.
Sufentanil
One of the eligible studies was an editorial letter by White et al. published in 2008 [22] . The authors had retrospectively reviewed the records of 48 cancer patients in a hospital palliative care setting in UK. They assessed the use of sufentanil due to difficulties in using other opioids and generally described the effect on pain control following titrations as Bfavourable^.
Buprenorphine
A prospective parallel group, active-controlled study by Melilli et al. published in 2014 compared use of fentanyl with buprenorphine [14] . Forty-two cancer patients were consecutively enrolled at an outpatient clinic in Bologna, Italy. The patients had uncontrolled pain on NSAIDs and weak opioids and were unable to take oral opioids. Patients with renal impairment (serum creatinine ≥1.3 mg/dl) were commenced on transdermal buprenorphine, while patients with no renal impairment (s-creatinine ≤1.2 mg/dl) were started on transdermal fentanyl (T0). Patients were followed up after 10 days (T1), 30 days (T2) and 90 days (T3). The authors found a significant reduction in NRS-score (0-10) over time in both groups (t test; T0-T1, T1-T2 and T2-T3; p < 0.0001, p < 0.001 and p < 0.05, respectively). At all times, there were no significant differences in pain scores between the groups (T0, p = 0.6225; T1, p = 0.0639; T2, p = 0.7838 and T3, p = 0.9194). The number of cases with side effects was similar in both groups and were reported to decrease over time. At all times, no statistically significant association was found between the reported side effects and the treatment groups (X 2 test: T1, p = 0.2897; T2, p = 0.4252; T3, p = 0.2220). The most common side effects were somnolence/confusion, nausea/ vomiting, constipation and pruritus.
Hydromorphone
Two studies examined aspects of hydromorphone [13, 16] . The study by Lee et al. from 2001 was a retrospective review of records of 55 palliative care patients who had been switched to oral hydromorphone, most often from morphine [13] . The major reason for a change to hydromorphone treatment was found to be side effects on previous therapy (cognitive, drowsiness and/or nausea). Following the switch, these side effects improved in >80 % of patients (hallucinations improved in 100 %; drowsiness in 85 %; nausea in 89 %; pain in 83 % (pain only documented in 42 patients)). Patients with renal impairment (urea >10.5 mmol/l and/or creatinine ≥101 mmol/l) were compared with patients with no renal impairment, and the reasons for a switch to hydromorphone were similar in both groups. There was also an improvement in the side effect profile in >80 % of patients in the renal impairment group.
The study by Paramanandam et al. published in 2011 was a retrospective review of 54 in-patients' records at a hospice in USA [16] . The patients had renal insufficiency (GFR <60 ml/ min/1.73 m 2 ) and were treated with hydromorphone via continuous parenteral infusion. The authors assessed the prevalence of symptoms of neuroexcitation. Tremor had been present in 11/54 (20 %) of patients, myoclonus in 11/54 (20 %), agitation in 26/54 (48 %) and cognitive dysfunction in 21/54 (39 %). A strong and graded increase was found in neuroexcitatory symptoms with increasing dose or increasing duration of hydromorphone treatment for agitation (dose, p < 0.001; duration, p < 0.0001) and cognitive dysfunction (dose, p < 0.0002; duration, p < 0.002).
Meperidine (pethidine)
One of the studies retrieved was an uncontrolled prospective study by Kaiko et al. published in 1982 , where 67 patients (19 of them had cancer) treated with meperidine for pain relief were included from a cancer pain centre in New York, USA. The authors assessed the relationship between signs and symptoms of CNS excitation and plasma levels of meperidine and normeperidine. Patients with symptoms of CNS excitation received meperidine for a longer period (p < 0.001) and at a higher rate (p < 0.001) than did asymptomatic patients. The authors found no difference in the duration or rate of meperidine administration between groups with different intensity of CNS symptoms. Symptomatic patients also had a higher normeperidine plasma level (p < 0.001) than did asymptomatic patients. There was an association between high normeperidine-to-meperidine ratios and elevated (>1.7 mg/ dl) serum creatinine in symptomatic patients (p < 0.05).
Opioids in general
Twomey et al. examined prescribing practice in patients with significant renal impairment (serum urea >10 mmol/l and serum creatinine >150 μmol/l) [24] . The authors reviewed the records of 40 patients at 2 specialist palliative care units in UK. Opioids had been prescribed in 34/40 (85 %) of patients, codeine/morphine/diamorphine in 18/34 (53 %), oxycodone in 9/34 (26 %) and a combination in 7/34 (21 %). A total of 13/ 34 (38 %) of patients developed opioid toxicity.
Discussion
There is limited evidence upon which to base clinical practice when using opioids in patients with cancer with co-existing renal impairment [11, 12, 16] . However, despite this scarce clinical evidence, several guidelines and recommendations have been published on opioid treatment in cancer patients with renal impairment [3, 4, 27, 28] . These guidelines and recommendations are based on clinical experience and indirect pharmacological evidence, rather than clinical studies.
A previous systematic review undertaken in 2009 echoes the findings of this present review [29] . However, it is important to emphasise that despite of the lack of evidence demonstrated previously, little has been done to move forward the research agenda.
Nevertheless, clinicians still use opioids in patients with renal impairment and based on the evidence appraised as part of this review, we present key clinical questions and evidence presented in relation to these.
Should morphine be avoided in patients with renal impairment?
From the studies identified, it is clear that this is a difficult area, with a substantial disagreement within the existing literature. Two of the retrieved studies demonstrated a relationship between an increased creatinine level and higher concentrations of M3G and M6G [8, 20] , while Somogyi et al. found no relationship between creatinine clearance and clearance of morphine, M3G or M6G [19] . Three studies found a relationship between increased creatinine level and morphine-related side effects [12, 17, 23] , while others demonstrated no relationship [11, 18, 20, 23] . The unclear relationship between morphine, creatinine levels and morphine-related side effects raises the question if morphine has got a worse reputation than it deserves. It is clear that more evidence is needed before morphine's role in the treatment of cancer patients with renal impairment is fully understood. Based on the current evidence, morphine should however be used with caution in these patients.
Is oxycodone safe to use in renal impairment?
Oxycodone is metabolised in the liver, and due to a conception that it has fewer effects from accumulating metabolites than do morphine, it has been recommended as an effective alternative to morphine in cancer pain [30] [31] [32] . However, the situation is not that clear. Other studies have shown that the elimination of oxycodone in renal impairment is significantly prolonged, and excretion of its metabolites is severely impaired [33] . The results from the studies retrieved in the present systematic review were also inconclusive. Narabayashi et al. did not find any significant correlation between creatinine clearance and oxycodone or its metabolites. On the other hand, Kurita et al. found that increased serum concentrations of oxycodone were associated with increased side effects in the form of severe fatigue. Based on this inconclusive picture, caution is recommended for oxycodone in cancer patients with renal impairment.
Are fentanyl, alfentanil and/or sufentanil the drugs of choice in renal impairment?
Both fentanyl, alfentanil and sufentanil have been recommended in guidelines on treatment of cancer pain in patients with renal impairment [4, 27, 28] . These three opioids are metabolised in the liver. Their metabolites have minimal or no pharmacologic effect and are excreted in urine (for sufentanil also in bile) [34] [35] [36] . The pharmacokinetics of these opioids are largely unchanged in patients with renal impairment and have therefore been seen as favourable in these patients [36] . It is striking how incorporated this practice seems to be, despite very little clinical evidence. In the present systematic review, only two studies were found investigating clinical aspects of fentanyl [12, 25] , two studies on alfentanil [10, 21] and one editorial letter on sufentanil [22] . The clinical evidence from these studies are scarce and of very low quality. However, pharmacokinetics and clinical experience point in the direction that these opioids are a recommended alternative in cancer patients with renal impairment.
Is there a role for hydromorphone or methadone in patients with renal impairment?
T h e p r i m a r y m e t a b o l i t e o f h y d r o m o r p h o n e i s hydromorphone-3-glucuronide (H3G). Hydromorphone and H3G are primarily excreted by the kidneys and accumulate in renal impairment [37] . H3G is believed to have no analgesic effect but contributes to neuroexcitatory adverse effects as myoclonus, seizures, allodynia, sedation and cognitive impairment [37] . The limited studies retrieved in the present systematic review found inconclusive data regarding side effects. Lee et al. found that a switch to hydromorphone (mostly from morphine) improved the side effect profile in >80 % of patients [13] . Paramanandam et al. found that the prevalence of neuroexcitatory symptoms increased with increased dose or increased duration of the hydromorphone treatment in cancer patients with renal impairment [16] . It is recommended to reduce the hydromorphone dose and monitor the patient carefully if treating cancer patients with renal impairment.
In this systematic review, no studies on methadone in cancer patients with renal impairment were retrieved. Methadone is mainly metabolised in liver, but elimination through the kidneys is also observed. The metabolites are inactive or considered of no clinical significance. However, methadone has a very long and unpredictable half-life. After initiation of methadone, or increase of the dose, plasma concentration rises over a prolonged period, which may be associated with a delayed onset of side effects and potential drug accumulation and toxicity. There is still a debate regarding the equianalgesic dose ratio of morphine to methadone and the right interval between doses [38, 39] . Due to these factors, methadone is in general recommended to be prescribed only by experienced clinicians and with close follow-up of the patients. Patients with renal impairment are in general more complex, and caution is recommended.
What opioid should be used in patients receiving treatment with dialysis?
This systematic review did not include cancer patients receiving dialysis treatment. For these patients, removal of the drug will depend on the opioids' molecular size, water solubility, volume of distribution and protein binding [40] . Hydromorphone has been recommended as an opioid of choice in patients treated with dialysis. It has low protein binding, low molecular weight and a low volume of distribution. Dialysis therefore limits accumulation and side effects [41] . Fentanyl has also been advocated as a safe option due to its high protein binding, low water solubility, a high volume of distribution and a moderately high molecular weight [42] . Independent of which opioid, titration is recommended to start at low doses, with an increased dosing interval and with close monitoring for side effects. Morphine, hydrocodone and meperidine are not recommended in patients receiving dialysis treatment.
Future studies and design considerations
There are several challenges with carrying out studies in this field. In general, conducting trials in patients with advanced cancer is challenging, as patients are often frail, which makes it more difficult to take part in different assessments. This results in challenges with both recruitment and attrition.
There is a need for high-quality randomised controlled trials (RCTs) in this field. An RCT comparing morphine treatment with oxycodone and/or fentanyl/alfentanil in cancer patients with renal impairment is a crucial first step. Cancer patients with renal impairment are complex, and there are several challenges with conducting a study with this patient population. One consideration is classification of renal impairment using glomerular filtration rate (GFR) or creatinine clearance. It is recommended to assess renal function by estimation of glomerular filtration rate (GFR) [43] . Another important issue is defining the optimal outcome measure(s). The most relevant as a primary outcome would be opioid toxicity measured by degree of opioid-related side effects. As secondary end points, both level of achieved analgesia and metabolites quantified from blood samples would be of interest.
Several of the studies in the present review showed some influence from renal impairment on drug and metabolite serum concentrations, but no corresponding influence on symptoms [11, 18, 20, 23] . There might be several design-related explanations for this, as small number of patients included or confounding effects from other patient-related factors as pain mechanisms, anti-tumour treatment, metabolic status or hydration. However, opioid pharmacology is influenced by genetic variability, which might also be an explanatory factor [44, 45] . Receptor properties or intracellular pharmacodynamic factors might have caused variability in the clinical outcomes [46] [47] [48] .
All systematic reviews have got limitations associated with the search strategy. The exclusion criteria can potentially have left out relevant studies. As with all systematic reviews, language bias or publication bias can be present. One of the other main challenges is that there is heterogeneity of both populations studied and classification of renal impairment. We set out to classify all studies as per the KDIGO guidelines; however, this was rarely possible and is a limitation. We would suggest that future studies use this classification.
Conclusion
The present systematic review demonstrates low quality on the existing evidence on opioid treatment in cancer patients with renal impairment. There remains a need for high-quality studies to be carried out before any evidence-based guidelines can be established.
